1. Scrip

uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed

Dutch Group Gets $450m Upfront For Gene Therapy

 
• By Kevin Grogan

Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.

Genetic breakthrough and medical gene therapy treatment discovery concept as a dart hitting a target by breaking a double helix representing genes as a 3D illustration.
CSL hopes hemophilia B gene therapy will hit the target • Source: Shutterstock

The likelihood of a uniQure NV buyout, regularly touted as a takeover target for big pharma, looks to have diminished after the Dutch firm plumped instead for a licensing agreement with blood plasma major CSL Behring for etranacogene dezaparvovec, its gene therapy for patients with hemophilia B.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Advanced Therapies